(Q41624139)

5 October 2017

1 reference

title

Medical therapy of gastroesophageal reflux and management of esophageal strictures (English)

1 reference

5 October 2017

Wo JM

1

1 reference

PubMed ID

9347830

5 October 2017

Waring JP

series ordinal

2

1 reference

5 October 2017

1 October 1997

1 reference

Surgical Clinics of North America

5 October 2017

1 reference

5 October 2017

77

1 reference

5 October 2017

5

1 reference

5 October 2017

1041-1062

1 reference

Current medical therapy for esophageal motility disorders

5 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

A controlled trial of corticosteroids in children with corrosive injury of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Are H2 receptor antagonists safe over the counter drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effect of smoking in a controlled study of ranitidine treatment in gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effect of theophylline on gastroesophageal reflux in normal adults

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Drug-induced esophageal strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Analysis of 24-hour esophageal pressure and pH data in unselected patients with noncardiac chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Cutting the defiant lower esophageal ring

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Imipramine in patients with chest pain despite normal coronary angiograms

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Evaluation of dysphagia: A careful history is crucial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Contact ulcer of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Pathogenesis of coffee-induced gastrointestinal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Gastric Acid Secretion and Lower-Esophageal-Sphincter Pressure in Response to Coffee and Caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Biomechanics of cricopharyngeal bars

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Esophageal motility impairment in Plummer-Vinson syndrome. Correction by iron treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Experimentally produced vocal cord granulomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Single dilation of symptomatic Schatzki rings. A prospective evaluation of its effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effects of ranitidine treatment on patients with asthma and a history of gastro-oesophageal reflux: a double blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Influence of theophylline on gastro-oesophageal reflux and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease: "for whom the bell tolls"

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effect of cisapride, a new prokinetic agent, on esophageal motor function

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Lack of effect of metoclopramide and domperidone on esophageal peristalsis and esophageal acid clearance in reflux esophagitis. A randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Schatzki's ring: long-term results following dilation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Outcomes of antireflux therapy for the treatment of chronic laryngitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Antireflux treatment for asthma. Improvement in patients with associated gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Fluoroscopy is not necessary for Maloney dilation of chronic esophageal strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Effect of cisapride on postprandial gastro-oesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Chronic cough as the sole presenting manifestation of gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Proximal esophageal pH-metry in patients with 'reflux laryngitis'

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Simultaneous tracheal and oesophageal pH measurements in asthmatic patients with gastro-oesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Safety experience from long-term treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Evaluation of elevation of the head of the bed, bethanechol, and antacid foam tablets on gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Esophageal dilation with polyvinyl bougies using a guidewire with markings without the aid of fluoroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Mechanisms of acid reflux associated with cigarette smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole for the treatment of posterior laryngitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Cisapride stimulates human esophageal motility

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Body position affects recumbent postprandial reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Rationale and Efficacy of Conservative Therapy for Gastroesophageal Reflux Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Lipoinjection for vocal card paralysis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Hydrostatic balloon dilation of gastrointestinal stenoses: a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Gastroesophageal reflux in runners. Characteristics and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Preliminary experience with endoscopic intralesional steroid injection therapy for refractory upper gastrointestinal strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Treatment of severe reflux esophagitis with cimetidine and metoclopramide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Does massive obesity promote abnormal gastroesophageal reflux?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Gastroesophageal reflux as a pathogenic factor in the development of symptomatic lower esophageal rings

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Does fluoroscopic guidance for Maloney esophageal dilation impact on the clinical endpoint of therapy: relief of dysphagia and achievement of luminal patency.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Prospective randomized study of Maloney esophageal dilation--blinded versus fluoroscopic guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Pathophysiological effects of long-term acid suppression in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Pill-induced esophageal strictures: clinical features and risk factors for development

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Single dose treatment with H2 receptor antagonists: is bedtime administration too late?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Marked wire-guided esophageal dilation and the need for fluoroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Symptomatic gastroesophageal reflux: incidence and precipitating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

The hiatus hernia-esophagitis-esophageal stricture complex. Twenty-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Combined ambulatory esophageal manometry and dual-probe pH-metry in evaluation of patients with chronic unexplained cough

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Spontaneous noncardiac chest pain. Evaluation by 24-hour ambulatory esophageal motility and pH monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

An algorithmic approach to chronic cough.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Esophageal chest pain: current controversies in pathogenesis, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Prospective randomized comparison of polyvinyl bougies and through-the-scope balloons for dilation of peptic strictures of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Dental erosion and acid reflux disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Comparison between Savary-Gilliard and balloon dilatation of benign esophageal strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Gastroesophageal reflux disease and asthma. Diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Dilation of esophageal strictures induced by radiation therapy for cancer of the esophagus.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Healing and prevention of relapse of reflux oesophagitis by cisapride

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Complications of esophageal dilation and guidelines for their prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

A comparison of five maintenance therapies for reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

1 reference

7 January 2021

Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Esophageal dilation in the sitting, sedated patient is safe and effective

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Tolerance to oral H2-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Multicenter trial of sucralfate suspension for the treatment of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Features of symptomatic gastroesophageal reflux in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

Endoscopic techniques and complications in variceal sclerotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970604-6

7 January 2021

10.1016/S0039-6109(05)70604-6

Identifiers

DOI

1 reference

5 October 2017

1 reference

PubMed ID

9347830